GANFENGLITHIUM (01772.HK): VP's reduction plan expires without implementation, holding unchanged at 215,050 shares
NewTimeSpace News: On 4 September 2026, Ganfeng Lithium Group Co., Ltd. (stock code: 01772) announced that the share reduction plan of Mr. Fu Lihua, vice president of the Company, has expired without implementation. The Company disclosed the pre-announcement of the reduction on 13 May 2026, under which Mr. Fu planned to reduce up to 40,000 shares (representing no more than 0.002% of the Company's total share capital) through centralised bidding, during the period from 4 June 2026 to 3 September 2026.
As of the date of this announcement, the reduction plan period has expired, and Mr. Fu has not reduced any of his shareholding in the Company. Both before and after the reduction period, Mr. Fu held an aggregate of 215,050 shares (representing 0.010% of the total share capital), comprising 53,762 unrestricted shares (0.002%) and 161,288 restricted shares (0.008%).
The Company noted that the reduction plan had been pre-disclosed in accordance with regulations, and Mr. Fu's failure to reduce his shareholding during the plan period does not constitute any breach of the reduction plan or related commitments.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CH BIOTECH SER (08037.HK): Penbo (Hainan) BNCT hospital enters into cross-border oncology cooperation agreement with Hong Kong Oncare
- Ganfeng Lithium (01772.HK): Ganfeng Lithium Battery Participates in Investment in Limited Partnership with Capital Commitment of RMB 100 Million
- CH BIOTECH SER (08037.HK): Enters master cooperation agreement with Stella Pharma to develop and commercialize Steboronine®, world's first approved BNCT drug, in China
- JINTAI ENERGY H (02728.HK): Revised Expected Timetable for Share Consolidation, Circular to Be Despatched on 21 August, Consolidation Effective 15 September
- Dongheng New Energy Receives CSRC International Department Supplementary Filing Requirements, Covering Three Items Including Subscription Prices of New Shareholders, Shareholding Nomination and "Two High" Projects